COMERA LIFE SCIENCES HLDG (CMRA) Financials
Newest figures come from the 10-Q for Q3 FY2023, filed Nov 9, 2023. Each column of the statement tables below links to the filing it was taken from.
COMERA LIFE SCIENCES HLDG (CMRA) reported $1.0M in revenue over the twelve months to Sep 30, 2023. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Development-stage economics are improving at the gross-profit level, but overhead and financing needs overwhelm a tiny revenue base.
Revenue nearly doubled from FY2021 to FY2022 while gross margin rose from49.7% to66.8% , yet operating losses widened: the added gross profit was absorbed by corporate spending rather than converted into operating leverage. That combination points to better production economics without evidence that the current cost structure scales with revenue.
R&D exceeded FY2022 revenue by nearly three times, marking a development-stage cost structure rather than a volume-funded operating model. Operating cash flow and free cash flow were almost identical, so cash consumption was overwhelmingly operational, not driven by capital investment; the reported liquidity comparison was just 0.5 months of annual operating outflow.
The balance sheet is structurally strained: current ratio fell from 6.5x in FY2021 to 0.6x in FY2022, showing sharply reduced short-term flexibility. Liabilities exceeded assets in FY2022 and negative equity remained, so financing structure shaped the reported position as much as product development.
Financial Health Signals
COMERA LIFE SCIENCES HLDG does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
COMERA LIFE SCIENCES HLDG scores -24.18, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($6K) relative to total liabilities ($10.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
COMERA LIFE SCIENCES HLDG passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
COMERA LIFE SCIENCES HLDG reported a net loss of $18.0M while operations used $9.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
COMERA LIFE SCIENCES HLDG reported an operating loss of $12.0M against $20K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
COMERA LIFE SCIENCES HLDG generated $136K in revenue in Q3 2023. This represents a decrease of 42.0% from the same quarter a year earlier. Against the prior quarter it is down 56.7%.
COMERA LIFE SCIENCES HLDG's EBITDA was -$2.1M in Q3 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 15.0% from the same quarter a year earlier. Against the prior quarter it is down 46.6%.
COMERA LIFE SCIENCES HLDG reported -$2.2M in net income in Q3 2023. This represents an increase of 30.0% from the same quarter a year earlier. Against the prior quarter it is down 52.6%.
COMERA LIFE SCIENCES HLDG earned -$0.10 per diluted share (EPS) in Q3 2023. This represents an increase of 50.0% from the same quarter a year earlier. Against the prior quarter it is down 25.0%.
Cash & Balance Sheet
COMERA LIFE SCIENCES HLDG recorded an outflow of $1.9M in free cash flow in Q3 2023, representing a cash shortfall after capex. This represents an increase of 20.7% from the same quarter a year earlier. Against the prior quarter it is down 91.6%.
COMERA LIFE SCIENCES HLDG held $1.8M in cash as of Q3 2023; long-term debt is not reported for that period.
Not reported for Q3 2023.
Margins & Returns
COMERA LIFE SCIENCES HLDG's gross margin was 69.2% in Q3 2023, indicating the percentage of revenue retained after direct costs. This is down 4.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 13.0 percentage points.
Not shown for Q3 2023: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2023: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q3 2023.
Capital Allocation
COMERA LIFE SCIENCES HLDG invested $366K in research and development in Q3 2023. This represents a decrease of 7.3% from the same quarter a year earlier. Against the prior quarter it is up 55.3%.
COMERA LIFE SCIENCES HLDG reported no capital expenditure in Q3 2023. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Not reported for Q3 2023.
CMRA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $136K-42.0% | $315K+114.7% | $393K+312.1% | $156K | $235K+167.7% | $147K+106.9% | $95K | N/A |
| Cost of Revenue | $42K-31.2% | $56K+2.7% | $117K+161.7% | $50K | $61K+26.1% | $55K-5.3% | $45K | N/A |
| Gross Profit | $94K-45.8% | $259K+181.0% | $276K+444.0% | $106K | $174K+341.5% | $92K+590.5% | $51K | N/A |
| R&D Expenses | $366K-7.3% | $236K-36.0% | $344K-29.5% | $489K | $395K+49.8% | $369K-45.8% | $487K | N/A |
| SG&A Expenses | $1.9M-18.5% | $1.5M-59.3% | $2.4M+20.7% | $2.6M | $2.3M+235.7% | $3.7M+198.7% | $2.0M | N/A |
| Operating Income | -$2.2M+14.9% | -$1.5M+62.7% | -$2.5M-1.9% | -$3.0M | -$2.5M-177.5% | -$4.0M-108.7% | -$2.5M | N/A |
| EBITDA | -$2.1M+15.0% | -$1.5M+63.2% | -$2.5M-1.8% | -$3.0M | -$2.5M-180.7% | -$4.0M | -$2.4M | N/A |
| Interest Expense | $6K-53.0% | $4K | $8K+9793.5% | N/A | $13K | N/A | $77 | N/A |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A |
| Net Income | -$2.2M+30.0% | -$1.4M+84.5% | -$2.5M+13.8% | -$3.0M | -$3.1M-236.7% | -$9.1M-358.7% | -$2.9M-439.8% | N/A |
| EPS (Basic) | -$0.10+50.0% | -$0.08+93.0% | -$0.13+96.8% | $0.09+109.6% | -$0.20+96.8% | -$1.14-67.6% | -$4.01 | -$0.94 |
| EPS (Diluted) | -$0.10+50.0% | -$0.08 | -$0.13 | $0.09 | -$0.20 | -$1.14 | -$4.01 | -$0.94 |
| Diluted Shares (Avg) | 23M+44.2% | 19M | 19M | N/A | 16M | 8M | 718,419 | N/A |
CMRA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.1M-37.8% | $2.3M-61.8% | $3.0M | $3.7M-49.8% | $4.9M | $6.1M | N/A | $7.4M+1258.9% |
| Current Assets | $2.6M-38.7% | $1.8M-66.3% | $2.4M | $3.1M-54.8% | $4.3M | $5.4M | N/A | $6.8M+2084.7% |
| Cash & Equivalents | $1.8M-33.8% | $476K-90.4% | $1.5M-60.2% | $447K-93.1% | $2.7M-67.7% | $4.9M-28.7% | $3.9M | $6.5M+4088.6% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | N/A | $250K+150.0% | N/A | $34K | $294K | $100K | N/A | $0-100.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $7.3M-12.8% | $8.7M+9.7% | $8.3M | $10.0M-54.9% | $8.4M | $7.9M | N/A | $22.1M+5510.7% |
| Current Liabilities | $2.9M-14.5% | $4.0M+56.6% | $3.4M | $5.1M+384.0% | $3.4M | $2.5M | N/A | $1.0M+347.8% |
| Non-Current Liabilities | $4.4M-11.6% | $4.7M-12.3% | $4.9M | $4.9M-76.7% | $4.9M | $5.4M | N/A | $21.1M+13013.7% |
| Total Equity | -$4.2M-23.1% | -$6.4M-254.4% | -$5.3M+69.2% | -$6.2M+57.5% | -$3.4M+74.9% | -$1.8M+85.1% | -$17.1M-4549.9% | -$14.7M-9767.4% |
| Retained Earnings | -$41.0M-28.2% | -$38.8M-34.4% | -$37.4M | -$34.9M-106.5% | -$31.9M | -$28.9M | N/A | -$16.9M-47.6% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
CMRA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.9M+19.9% | -$994K+62.7% | -$1.9M+33.6% | -$1.8M-15.2% | -$2.4M-155.9% | -$2.7M | -$2.9M | -$1.6M |
| Depreciation & Amortization | $23K-4.2% | $25K+13.6% | $28K+14.1% | $24K-1.8% | $24K+25.3% | $22K | $25K | $24K |
| Stock-Based Compensation | $268K+109.5% | $279K+391.7% | $301K+606.8% | N/A | $128K+272.4% | $57K-94.5% | $43K | N/A |
| Capital Expenditures | $0-100.0% | $6K | $88K | $0-100.0% | $25K | N/A | N/A | $131K |
| Free Cash Flow | -$1.9M+20.7% | -$999K | -$2.0M | -$1.8M-6.6% | -$2.4M | N/A | N/A | -$1.7M |
| Investing Cash Flow | $0+100.0% | -$6K | -$88K | $0+100.0% | -$25K | N/A | N/A | -$131K |
| Financing Cash Flow | $3.2M+2108.3% | -$63K-101.7% | $1.6M+610.3% | $1.1M | $145K-93.7% | $3.7M | $223K | $0 |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CMRA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 69.2%-4.8pp | 82.2%+19.4pp | 70.3%+17.0pp | 67.7% | 74.1%+29.2pp | 62.8%+44.0pp | 53.3% | N/A |
| Operating Margin | -1582.5% | -469.8% | -636.4% | -1927.4% | -1079.3% | -2707.7% | -2572.7% | N/A |
| Net Margin | -1580.0% | -448.1% | -631.5% | -1897.6% | -1309.7% | -6192.0% | -3020.3% | N/A |
| Return on Assets | -70.1%-7.8pp | -60.3%+87.9pp | -82.7% | -79.5% | -62.3% | -148.2% | N/A | N/A |
| Current Ratio | 0.90-0.4x | 0.46-1.7x | 0.72 | 0.61-5.9x | 1.25 | 2.14 | N/A | 6.49+5.2x |
| Asset Turnover | 0.040.0x | 0.13+0.1x | 0.13 | 0.04 | 0.05 | 0.02 | N/A | N/A |
| FCF Margin | -1404.2% | -317.1% | -507.5% | -1183.5% | -1027.8% | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$6.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.61), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| COMERA LIFE SCIENCES HLDG CMRA | FY2022 | $633K | -$18.0M | N/A | $6K | — |
| NOVACCESS GLOBAL INC XSNX | FY2024 | $0 | N/A | N/A | $6K | — |
| BETTER THERAPEUTICS INC BTTX | FY2022 | N/A | -$39.8M | N/A | $5K | — |
| EVELO BIOSCIENCES INC EVLO | FY2022 | N/A | -$114.5M | N/A | $9K | — |
| RENOVACARE INC RCAR | FY2021 | N/A | -$4.5M | N/A | $9K | — |
Where COMERA LIFE SCIENCES HLDG Ranks
Frequently Asked Questions
What is COMERA LIFE SCIENCES HLDG's annual revenue?
COMERA LIFE SCIENCES HLDG (CMRA) reported $633K in total revenue for fiscal year 2022. This represents a 97.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is COMERA LIFE SCIENCES HLDG's revenue growing?
COMERA LIFE SCIENCES HLDG (CMRA) revenue grew by 97.9% year-over-year, from $320K to $633K in fiscal year 2022.
Is COMERA LIFE SCIENCES HLDG profitable?
No, COMERA LIFE SCIENCES HLDG (CMRA) reported a net income of -$18.0M in fiscal year 2022.
What is COMERA LIFE SCIENCES HLDG's EBITDA?
COMERA LIFE SCIENCES HLDG (CMRA) had EBITDA of -$11.9M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.
What is COMERA LIFE SCIENCES HLDG's gross margin?
COMERA LIFE SCIENCES HLDG (CMRA) had a gross margin of 66.8% in fiscal year 2022, indicating the percentage of revenue retained after direct costs of goods sold.
What is COMERA LIFE SCIENCES HLDG's free cash flow?
COMERA LIFE SCIENCES HLDG (CMRA) recorded an outflow of $9.8M in free cash flow during fiscal year 2022. This represents a -151.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is COMERA LIFE SCIENCES HLDG's operating cash flow?
COMERA LIFE SCIENCES HLDG (CMRA) recorded an outflow of $9.8M in operating cash flow during fiscal year 2022, representing cash used by core business activities.
What are COMERA LIFE SCIENCES HLDG's total assets?
COMERA LIFE SCIENCES HLDG (CMRA) had $3.7M in total assets as of fiscal year 2022, including both current and long-term assets.
What are COMERA LIFE SCIENCES HLDG's capital expenditures?
COMERA LIFE SCIENCES HLDG (CMRA) invested $29K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.
How much does COMERA LIFE SCIENCES HLDG spend on research and development?
COMERA LIFE SCIENCES HLDG (CMRA) invested $1.7M in research and development during fiscal year 2022.
What is COMERA LIFE SCIENCES HLDG's current ratio?
COMERA LIFE SCIENCES HLDG (CMRA) had a current ratio of 0.61 as of fiscal year 2022, which is below 1.0, which may suggest potential liquidity concerns.
What is COMERA LIFE SCIENCES HLDG's return on assets (ROA)?
COMERA LIFE SCIENCES HLDG (CMRA) had a return on assets of -483.1% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
How does COMERA LIFE SCIENCES HLDG's liquidity compare with its operating cash outflow?
At the end of fiscal year 2022, COMERA LIFE SCIENCES HLDG (CMRA) held $447K in cash, cash equivalents and investments, and reported an operating cash outflow of $9.8M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is COMERA LIFE SCIENCES HLDG's debt-to-equity ratio negative or not reported?
COMERA LIFE SCIENCES HLDG (CMRA) has negative shareholder equity of -$6.2M as of fiscal year 2022, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is COMERA LIFE SCIENCES HLDG's Altman Z-Score?
COMERA LIFE SCIENCES HLDG (CMRA) has an Altman Z-Score of -24.18, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is COMERA LIFE SCIENCES HLDG's Piotroski F-Score?
COMERA LIFE SCIENCES HLDG (CMRA) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are COMERA LIFE SCIENCES HLDG's earnings high quality?
COMERA LIFE SCIENCES HLDG (CMRA) reported a net loss of $18.0M while operations used $9.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can COMERA LIFE SCIENCES HLDG cover its interest payments?
COMERA LIFE SCIENCES HLDG (CMRA) reported an operating loss of $12.0M against $20K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.